Evercore ISI Group Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1150
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with an Outperform rating and a price target of $1150.
May 14, 2024 | 9:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group's initiation of coverage on Regeneron Pharmaceuticals with an Outperform rating and a price target of $1150 is a strong positive signal for the stock.
Analyst ratings, especially from reputable firms like Evercore ISI Group, can significantly influence investor sentiment and stock prices. An Outperform rating coupled with a high price target suggests a strong confidence in the company's future performance, potentially leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100